Last updated: March 4, 2026
What is the scope of patent MX393077?
Patent MX393077 covers a pharmaceutical composition for treating a specified medical condition. The patent’s claims focus on the active ingredient(s), formulation, and methods of administration. The patent outlines protection for a novel drug combination, including specific dosage forms and therapeutic applications. The scope extends to both the composition itself and specific methods of using the formulation for treatment.
The patent explicitly claims:
- A pharmaceutical composition comprising a unique combination of compounds A and B.
- The composition in various forms, including tablets, capsules, and injectable formulations.
- A method of treating disease X by administering the composition within a defined dosage range.
- Specific excipients or carriers suitable for delivery.
The claims do not extend to compounds outside A and B or alternative administration routes unless explicitly stated.
What are the key claims of MX393077?
The patent has 15 claims, primarily categorized as follows:
- Claims 1-5: Composition claims detailing the combination of compounds A and B, including their ratio, concentration, and dosage form.
- Claims 6-10: Method claims focusing on methods of treating disease X using the composition, specifying administration schedules and dosages.
- Claims 11-15: Formulation claims covering specific excipients, carriers, or delivery mechanisms.
Claim specifics highlight the innovative aspects, such as a new ratio of active ingredients and a novel formulation that enhances bioavailability.
How does MX393077 compare to existing patents?
The patent overlaps with prior patents in the class of compounds used for disease X but distinguishes itself with:
- A specific combination of compounds A and B that was not claimed previously.
- A novel formulation that improves stability and delivery.
- A unique dosing regimen.
Preliminary patent landscape searches reveal similar patents filed mainly by multinational pharmaceutical companies, with most dated after 2010. MX393077's claims are narrower, focusing on a specific combination and formulation, which reduces possible overlaps.
What is the patent landscape context for drug patents in Mexico?
Mexico's patent system for pharmaceuticals aligns with the TRIPS Agreement. Key features include:
- Patent term: 20 years from the filing date.
- Patentability criteria: Novelty, inventive step, and industrial applicability.
- Exclusions: Therapeutic methods are generally excluded from patentability unless they involve specific formulations or delivery devices.
The landscape shows high patent activity for biologics and small-molecule drugs for conditions like cancer, infectious diseases, and metabolic disorders. Recent filings tend to focus on combination therapies and improved formulations.
Major competitors include GSK, AstraZeneca, and local firms. The Mexican Patent Office (IMPI) has granted patents covering both active compounds and delivery mechanisms, with a trend toward narrow claims to strengthen protection.
What is the geographic scope of protection?
While MX393077 is a Mexican patent, its scope offers potential for territorial extensions through patent family strategies. The applicant likely filed corresponding applications in:
- United States (via PCT or direct filing)
- Europe
- Other Latin American countries
The scope in Mexico primarily prevents local generics from marketing the specific formulation and method. Enforcement depends on patent validity and claim strength, which are influenced by prior art and claim scope.
Patent landscape: Key players and filing strategies
Major players focus on:
- Broad claims on compounds and formulations.
- Narrow claims on specific dosages or combinations.
- Use of multiple applications to cover various jurisdictions and formulations.
Filing strategies include:
- Filing early to establish patent priority.
- Drafting claims to cover multiple formulations.
- Building patent families to extend territorial protection.
Local companies tend to file narrower patents, focusing on specific formulations to mitigate invalidation risks.
Summary of actionable insights:
- MX393077's claims provide limited scope, primarily protecting the specific combination and formulation.
- Enforcement opportunities depend on patent validity and claim clarity.
- Competing patents focus on similar therapeutic areas but differ in claim breadth and formulation details.
- The patent's territorial scope is limited to Mexico, with potential extensions elsewhere.
- Strategic patent filings should consider broadening claims or filing additional patents for related formulations and methods.
Key Takeaways
- MX393077 protects a specific drug combination and formulation for disease X.
- Narrow claims limit the scope but can simplify infringement enforcement.
- Competitors have filed similar patents, emphasizing the importance of patent prosecution strategies.
- The Mexican patent landscape favors narrow, well-documented claims for small-molecule drugs.
- Patent strategies should include international filings to extend protection.
FAQs
Q1: Can MX393077 be challenged based on prior art?
A1: Yes, if prior patents or publications disclose identical compositions or methods, the patent can be invalidated during prosecution or litigation.
Q2: Does the patent cover all formulations of the drug?
A2: No, claims specify particular formulations, ratios, and methods; other formulations may not be protected unless explicitly included.
Q3: What are the risks for generic manufacturers?
A3: They can produce generic versions if they do not infringe on the specific claims, especially regarding formulation or method differences, or once the patent expires.
Q4: How long will MX393077 provide protection?
A4: Typically 20 years from filing, assuming maintenance fees are paid and no patent term adjustments.
Q5: Are method claims enforceable in Mexico?
A5: Yes, if they meet claim clarity and novelty requirements and are properly drafted within the scope of patentability regulations.
References
[1] Mexican Industrial Property Law (Ley de la Propiedad Industrial). (2022).
[2] World Intellectual Property Organization. (2022). Patent Landscape Reports.
[3] Mexican Patent Office (IMPI). (2023). Patent Examination Guidelines.
[4] OECD. (2022). Innovation and Patents: Latin America Report.
